Application of Ropivacaine Combined with Nalbuphine Programmed Intermittent Epidural Bolus in Women with Vaginal Delivery
Objective To study the application effect of ropivacaine combined with nalbuphine programmed intermittent epidural bolus(PIEB)in women with vaginal delivery.Methods A total of 82 cases of parturient women with vaginal delivery in Xinxiang Maternal and Child Health Hospital from January 2022 to January 2023 were selected and divided into the control group(41 cases)and experimental group(41 cases)by random number table method.The control group received ropivacaine PIEB,and the experimental group received ropivacaine combined with nalbuphine PIEB.The visual simulation score(VAS)was compared between the two groups at different time periods[before labor analgesia(T0),30 minutes after analgesia(T,),1 hour after analgesia(T2),2 hours after analgesia(T3),the time of uterine full opening(T4),during labor(T5)].Labor time and frequency of controlled analgesia were compared between the two groups.The levels of serum pain mediator substance P(SP),β-Endorphin(β-Ep),incidence of adverse reactions,neonatal weight and neonatal Apgar score were compared between the two groups before labor analgesia and at the time of uterine full opening.Results Compared with the control group,VAS scores at T1,T2,T3,T4 and T5 in the experimental group were lower(P＜0.05).There was no significant difference in labor time between the two groups(P＞0.05).Compared with the control group,the number of controlled analgesia in the experimental group was less(P＜0.05).Compared with the control group,the levels of SP and β-Ep in the experimental group were lower at the time of uterine full opening(P＜0.05).There was no significant difference in the incidence of adverse reactions between the experimental group and the control group(P＞0.05).There were no significant differences in neonatal body weight and Apgar score between the two groups(P＞0.05).Conclusion Ropivacaine combined with nalbuphine PIEB can relieve pain symptoms,reduce the number of self-controlled analgesia,reduce maternal stress response,with fewer adverse reactions and no significant impact on neonatal outcomes.
万方数据
维普
